Oncolytic Virus Cancer Therapy Market

Leading companies in the oncolytic virus cancer therapy space include Targovax, Genelux, Imugene, EpicentRx, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, and Daiichi Sankyo. Therapies such as IMLYGIC (T-VEC), DELYTACT (G47Δ), Olvi-Vec, RP1, and others are expected to drive growth in the oncolytic virus cancer therapy market in the coming years.

DelveInsight has released a comprehensive report titled “Oncolytic Virus Cancer Therapy – Market Insights, Epidemiology, and Forecast to 2034”, providing detailed analysis of the disease, historical and projected epidemiology, and market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Discover about the Oncolytic virus cancer therapy market report @ https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Some of the key facts of the Oncolytic virus cancer therapy Market Report:

• The United States leads the global oncolytic virus market, accounting for over 70% of its total size, significantly outpacing regions such as the EU4, UK, and Japan. Oncolytic viruses provide several advantages over other cancer immunotherapies, including potent tumor-killing effects, targeted action, and fewer side effects or resistance issues.

• Currently, only two therapies—IMLYGIC (Amgen, approved 2015) and DELYTACT (Daiichi Sankyo, approved 2021)—have received global approval. However, the development pipeline is robust, with companies like Replimune, Genelux, Imugene, and EpicentRx driving innovation. Among these, RP1 is expected to capture roughly 40% of the market over the next decade.

• In November 2023, the FDA granted Fast Track designation to Genelux’s Olvi-Vec for the treatment of platinum-resistant or refractory ovarian cancer.

• According to GLOBOCAN, new breast cancer cases in the U.S. are projected to rise from 274,375 in 2022 to 321,295 by 2035. DelveInsight analysis also indicates that in 2023, prostate cancer accounted for about 20% of the total eligible patient population for oncolytic virus therapies across the seven major markets (7MM).

• Key companies developing new oncolytic virus cancer therapies include Targovax, Genelux, Imugene, EpicentRx, Replimune, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, Daiichi Sankyo, and others. Promising therapies in this space include IMLYGIC (T-VEC), DELYTACT (G47Δ), Olvi-Vec, RP1, and additional candidates.

Oncolytic virus cancer therapy Overview

Oncolytic viruses represent a distinct form of cancer therapy, functioning by selectively replicating within tumor cells, inducing immunogenic cell death, and stimulating the immune system to attack cancer. These viruses, whether naturally occurring or genetically engineered, specifically target and destroy malignant cells.

Although their mechanisms are not completely understood, oncolytic viruses primarily work through two pathways: directly destroying tumor cells (oncolysis) and indirectly enhancing the immune system’s response against tumors.

They are classified into RNA and DNA viruses. RNA viruses, including reoviruses, paramyxoviruses, and picornaviruses, replicate rapidly and quickly eliminate tumor cells but have limited genetic capacity. DNA viruses, such as herpesviruses, adenoviruses, and poxviruses, replicate more slowly but can carry multiple inserted genes, enabling more complex therapeutic approaches.

Oncolytic virus cancer therapy Market Outlook

As cancer continues to be a leading cause of death worldwide, the need for innovative therapies is growing. Oncolytic viruses (OVs), which selectively infect and destroy cancer cells while stimulating the immune system, have emerged as a promising treatment approach. Market expansion is being driven by increased R&D activities, rising pharmaceutical investments, and a growing number of clinical trials.

Key milestones include the FDA and European approval of IMLYGIC (Amgen) in 2015 for unresectable melanoma, and Japan’s conditional approval of DELYTACT (Daiichi Sankyo) in 2021 for malignant glioma. These approvals highlighted the potential of genetically engineered viruses to both target tumors and activate immune responses.

Although these approvals represent significant progress, ongoing clinical trials by companies such as Replimune, DNAtrix, and SillaJen are broadening the scope of OVs across multiple cancer types, underscoring their evolving role in personalized oncology.

Discover how the Oncolytic virus cancer therapy market is rising in the coming years @ https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Oncolytic Virus Marketed Drugs

• IMLYGIC (T-VEC): Amgen

• DELYTACT (G47Δ): Daiichio Sankyo

Oncolytic virus cancer therapy Emerging Drugs

• Olvi-Vec: Genelux

• RP1: Replimune

Scope of the Oncolytic virus cancer therapy Market Report

• Study Period: 2020-2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Oncolytic virus cancer therapy Companies: Targovax, Genelux, Imugene, EpicentRx, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, Daiichio Sankyo, and others

• Key Oncolytic virus cancer therapy Therapies: IMLYGIC (T-VEC), DELYTACT (G47Δ), Olvi-Vec, RP1, and others

• Oncolytic virus cancer therapy Therapeutic Assessment: Oncolytic virus cancer therapy current marketed and Oncolytic virus cancer therapy emerging therapies

• Oncolytic virus cancer therapy Market Dynamics: Oncolytic virus cancer therapy market drivers and Oncolytic virus cancer therapy market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Oncolytic virus cancer therapy Unmet Needs, KOL’s views, Analyst’s views, Oncolytic virus cancer therapy Market Access and Reimbursement

To know what’s more in our Oncolytic virus cancer therapy report, visit https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Key benefits of the Oncolytic virus cancer therapy Market Report:

1. Oncolytic virus cancer therapy market report covers a descriptive overview and comprehensive insight of the Oncolytic virus cancer therapy Epidemiology and Oncolytic virus cancer therapy market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).

2. The Oncolytic virus cancer therapy market report provides insights into the current and emerging therapies.

3. The Oncolytic virus cancer therapy market report provides a global historical and forecasted market covering drug outreach in 7MM.

4. The Oncolytic virus cancer therapy market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Oncolytic virus cancer therapy market.

Got queries? Click here to know more about the Oncolytic virus cancer therapy market Landscape

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Oncolytic virus cancer therapy Patient Share (%) Overview at a Glance

5. Oncolytic virus cancer therapy Market Overview at a Glance

6. Oncolytic virus cancer therapy Disease Background and Overview

7. Oncolytic virus cancer therapy Epidemiology and Patient Population

8. Country-Specific Patient Population of Oncolytic virus cancer therapy

9. Oncolytic virus cancer therapy Current Treatment and Medical Practices

10. Unmet Needs

11. Oncolytic virus cancer therapy Emerging Therapies

12. Oncolytic virus cancer therapy Market Outlook

13. Country-Wise Oncolytic virus cancer therapy Market Analysis (2020–2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Oncolytic virus cancer therapy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Oncolytic virus cancer therapy Market Outlook 2034

Related Reports:

Oncolytic virus cancer therapy Pipeline Insights, DelveInsight

“Oncolytic virus cancer therapy Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Oncolytic virus cancer therapy market. A detailed picture of the Oncolytic virus cancer therapy pipeline landscape is provided, which includes the disease overview and Oncolytic virus cancer therapy treatment guidelines.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/